Sweet Bones: The Pathogenesis of Bone Alteration in Diabetes
- PMID: 27777961
- PMCID: PMC5061963
- DOI: 10.1155/2016/6969040
Sweet Bones: The Pathogenesis of Bone Alteration in Diabetes
Abstract
Diabetic patients have increased fracture risk. The pathogenesis underlying the status of bone alterations in diabetes mellitus is not completely understood but is multifactorial. The major deficits appear to be related to a deficit in mineralized surface area, a decrement in the rate of mineral apposition, deceased osteoid surface, depressed osteoblast activity, and decreased numbers of osteoclasts due to abnormal insulin signaling pathway. Other prominent features of diabetes mellitus are an increased urinary excretion of calcium and magnesium, accumulation of advanced glycation end products, and oxidative stress leading to sweet bones (altered bone's strength, metabolism, and structure). Every diabetic patient should be assessed for risk factors for fractures and osteoporosis. The pathogenesis of the bone alterations in diabetes mellitus as well as their molecular mechanisms needs further study.
Figures
Similar articles
-
[Diabetes Mellitus and bone metabolism].Clin Calcium. 2011 May;21(5):669-75. Clin Calcium. 2011. PMID: 21532115 Review. Japanese.
-
Bone disorders associated with diabetes mellitus and its treatments.Joint Bone Spine. 2019 May;86(3):315-320. doi: 10.1016/j.jbspin.2018.08.002. Epub 2018 Aug 8. Joint Bone Spine. 2019. PMID: 30098423 Review.
-
Effects of Type 1 Diabetes on Osteoblasts, Osteocytes, and Osteoclasts.Curr Osteoporos Rep. 2016 Dec;14(6):310-319. doi: 10.1007/s11914-016-0329-9. Curr Osteoporos Rep. 2016. PMID: 27704393 Free PMC article. Review.
-
Role of advanced glycation end products (AGEs) in osteoporosis in diabetes.Curr Drug Targets. 2011 Dec;12(14):2096-102. doi: 10.2174/138945011798829456. Curr Drug Targets. 2011. PMID: 22023404
-
Advanced Glycation End Products, Diabetes, and Bone Strength.Curr Osteoporos Rep. 2016 Dec;14(6):320-326. doi: 10.1007/s11914-016-0332-1. Curr Osteoporos Rep. 2016. PMID: 27704396 Free PMC article. Review.
Cited by
-
Associations between bone-alkaline phosphatase and bone mineral density in adults with and without diabetes.Medicine (Baltimore). 2018 Apr;97(17):e0432. doi: 10.1097/MD.0000000000010432. Medicine (Baltimore). 2018. PMID: 29702995 Free PMC article.
-
Hydroxycoumarin Scopoletin Inhibits Bone Loss through Enhancing Induction of Bone Turnover Markers in a Mouse Model of Type 2 Diabetes.Biomedicines. 2021 Jun 7;9(6):648. doi: 10.3390/biomedicines9060648. Biomedicines. 2021. PMID: 34200167 Free PMC article.
-
The Efficacy of Alendronate Versus Denosumab on Major Osteoporotic Fracture Risk in Elderly Patients With Diabetes Mellitus: A Danish Retrospective Cohort Study.Front Endocrinol (Lausanne). 2022 Jan 26;12:826997. doi: 10.3389/fendo.2021.826997. eCollection 2021. Front Endocrinol (Lausanne). 2022. PMID: 35154013 Free PMC article.
-
Different bone sites-specific response to diabetes rat models: Bone density, histology and microarchitecture.PLoS One. 2018 Oct 22;13(10):e0205503. doi: 10.1371/journal.pone.0205503. eCollection 2018. PLoS One. 2018. PMID: 30346963 Free PMC article.
-
oxLDL inhibits differentiation of mesenchymal stem cells into osteoblasts via the CD36 mediated suppression of Wnt signaling pathway.Mol Biol Rep. 2019 Jun;46(3):3487-3496. doi: 10.1007/s11033-019-04735-5. Epub 2019 Mar 7. Mol Biol Rep. 2019. PMID: 30847850
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical